KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer

The KEYNOTE 021 trial was a randomized phase II/III trial comparing docetaxel and pembrolizumab as a secondline treatment for non-small cell lung cancer (NSCLC) in which 202 institutions from 24 countries participated (1). Eligible patients were as follows: progression after treatment with platinum combination therapy, EGFRTKI or AKL-TKI; an age of 18 years or older; an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0/1; and programmed death-ligand 1 (PD-L1) with a tumor proportion score (TPS) of 1% or more.